Synthetic mRNAs for manipulating cellular phenotypes: An overview

New Biotechnology

Volumn 32, Issue 1, 2015, Pages 229-235

  Quabius, Elgar Susanne ^a   Krupp, Guido ^b  

^a UNIVERSITY OF KIEL   (Germany)

^b AmpTec GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CULTURE; DISEASE CONTROL; DISEASES; GENE THERAPY; STEM CELLS;

CELLULAR PHENOTYPES; DENDRITIC CELLS; HIGH QUALITY; HUMAN FIBROBLAST; INDUCED PLURIPOTENT STEM CELLS; INFECTIOUS DISEASE; QUALITY REQUIREMENTS; STRUCTURAL FEATURE;

MOLECULAR BIOLOGY;

MESSENGER RNA; SYNTHETIC MESSENGER RNA; UNCLASSIFIED DRUG;

ALLERGY; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; CARCINOGENESIS; CELL DIFFERENTIATION; CELL MANIPULATION; CELLULAR DISTRIBUTION; CELLULAR IMMUNITY; DENDRITIC CELL; FIBROBLAST; GENE THERAPY; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; INFECTION; INNATE IMMUNITY; NONHUMAN; PHENOTYPE; PLURIPOTENT STEM CELL; QUALITY CONTROL; RNA SEQUENCE; VACCINATION; ANIMAL; CELLS; CHEMISTRY; METABOLISM;

ANIMALS; CELLS; GENETIC THERAPY; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, INNATE; PHENOTYPE; RNA, MESSENGER;

EID: 84912080017     PISSN: 18716784     EISSN: 18764347     Source Type: Journal    
DOI: 10.1016/j.nbt.2014.04.008     Document Type: Article

References (36)

1. Bernal J.A. RNA-based tools for nuclear reprogramming and lineage-conversion: towards clinical applications. J Cardiovasc Transl Res 2013, 6:956-968.
2. Li M., Sancho-Martinez I., Belmonte J.C.I. Cell fate conversion by mRNA. Stem Cell Res Ther 2011, 2:5.
3. Wolff J.A., Malone R.W., Williams P., Chong W., Acsadi G., Jani A., et al. Direct gene transfer into mouse muscle in vivo. Science 1990, 247:1465-1468.
4. Pascolo S. Vaccination with Messenger RNA (mRNA). Handb Exp Pharmacol 2008, 183:221-235.
5. Kuhn A.N., Beiβert T., Simon P., Vallazza B., Buck J., Davies B.P., et al. mRNA as a versatile tool for exogenous protein expression. Curr Gene Ther 2012, 12:347-361.
6. Petsch B., Schnee M., Vogel A.B., Lange E., Hoffmann B., Voss D., et al. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat Biotechnol 2012, 30:1210-1216.
7. Diken M., Kreiter S., Selmi A., Türeci O., Sahin U. Antitumor vaccination with synthetic mRNA: strategies for itro and ivo preclinical studies. Methods Mol Biol 2013, 969:235-246.
8. Grudzien-Nogalska E., Kowalska J., Su W., Kuhn A.N., Slepenkov S.V., Darzynkiewicz E., et al. Synthetic mRNAs with superior translation and stability properties. Methods Mol Biol 2013, 969:55-72.
9. Warren L., Manos P.D., Ahfeldt T., Loh Y.H., Li H., Lau F., et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 2010, 7:618-630.
10. Kariko K., Muramatsu H., Ludwig J., Weissman D. Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic Acids Res 2011, 39:e142.
11. Cyranoski D. Japan to offer fast-track approval path for stem cell therapies. Nat Med 2013, 19:510.
12. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124:783-801.
13. Kawai T., Akira S. Antiviral signaling through pattern recognition receptors. J Biochem 2007, 141:137-145.
14. Yoneyama M., Fujita T. Structural mechanism of RNA recognition by the RIG-I-like receptors. Immunity 2008, 29:178-181.
15. Wilkins C., Gale M. Recognition of viruses by cytoplasmic sensors. Curr Opin Immunol 2010, 22:41-47.
16. Nallagatla S.R., Toroney R., Bevilacqua P.C. Regulation of innate immunity through RNA structure and the protein kinase PKR. Curr Opin Struct Biol 2011, 21:119-127.
17. Chung C.Y.J., Ysebaert D., Berneman Z.N., Cools N. Dendritic cells: cellular mediators for immunological tolerance. Clin Dev Immunol 2013, Article ID 972865. 10.1155/2013/972865.
18. Van Tendeloo V.F., Van de Velde A., Van Driessche A., Cools N., Anguille S., Ladell K., et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci USA 2010, 107:13824-13829.
19. Gilboa E., Vieweg J. Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol Rev 2004, 199:251-263.
20. Martinon F., Krishnan S., Lenzen G., Magné R., Gomard E., Guillet J.G., et al. Induction of virus-specific cytotoxic T lymphocytes ivo by liposome-entrapped mRNA. Eur J Immunol 1993, 23:1719-1722.
21. Van Gulck E., Vlieghe E., Vekemans M., Van Tendeloo V.F., Van De Velde A., Smits E., et al. mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients. AIDS 2012, 26:F1-F12.
22. Van Gulck E., Cools N., Atkinson D., Bracke L., Vereecken K., Vekemans M., et al. Interleukin-12p70 expression by dendritic cells of HIV-1-infected patients fails to stimulate gag-specific immune responses. Clin Dev Immunol 2012, 10.1155/2012/184979.
23. Weiss R., Scheiblhofer S., Roesler E., Weinberger E., Thalhamer J. mRNA vaccination as a safe approach for specific protection from type I allergy. Expert Rev Vaccines 2012, 11:55-67.
24. Kariko K., Buckstein M., Ni H., Weissman D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 2005, 23:165-175.
25. Kariko K., Muramatsu H., Welsh F.A., Ludwig J., Kato H., Akira S., et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther 2008, 16:1833-1840.
26. Nallagatla S.R., Bevilacqua P.C. Nucleoside modifications modulate activation of the protein kinase PKR in an RNA structure-specific manner. RNA 2008, 14:1201-1213.
27. Uzri D., Gehrke L. Nucleotide sequences and modifications that determine RIG-I/RNA binding and signaling activities. J Virol 2009, 83:4174-4184.
28. Hornung V., Ellegast J., Kim S., Brzózka K., Jung A., Kato H., et al. 5'-Triphosphate RNA is the ligand for RIG-I. Science 2006, 314:994-997.
29. Pichlmair A., Schulz O., Tan C.P., Näslund T.I., Liljeström P., Weber F., et al. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates. Science 2006, 314:997-1001.
30. Mandal P.K., Rossi D.J. Reprogramming human fibroblast to pluripotency using modified mRNA. Nat Protoc 2013, 8:568-582.
31. Beier H., Barciszewska M., Krupp G., Mitnacht R., Gross H.J. UAG read through during TMV RNA translation: isolation and sequence of two tRNAs with suppressor activity from tobacco plants. EMBO J 1984, 3:351-356.
32. Yoshioka N., Gros E., Li H.R., Kumar S., Deacon D.C., Maron C., et al. Efficient generation of human iPSCs by synthetic self-replicative RNA. Cell Stem Cell 2013, 13:246-254.
33. Tavernier G., Andries O., Demeester J., Sanders N.N., De Smedt S.C., Rejman J. mRNA as gene therapeutic: how to control protein expression. J Control Release 2011, 150:238-247.
34. Kormann M., Hasenpusch G., Aneja M.K., Nica G., Flemmer A.W., Herber-Jonat S., et al. Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nat Biotechnol 2011, 29:154-157.
35. Rudolph C, Kormann M. RNA with a combination of unmodified and modified nucleotides for protein expression. WO 2011/012316 A2.
36. Kariko K., Muramatsu H., Keller J.M., Weissman D. Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin. Mol Ther 2012, 20:948-953.